BillionToOne Raises Revenue Outlook, Plans Blood Test
The company's oncology diagnostics business is growing while keeping accumulated losses small relative to public peers, and its blood-draw test is planned for December 2026.
Updated on Nov. 15, 2026 in Biotech

BillionToOne raised its full-year 2026 revenue guidance to between $460 million and $470 million after reporting third-quarter results on its November 4, 2026 earnings call. Total revenue grew 47% year over year to $123 million, and the company reported its fifth consecutive quarter of positive GAAP operating income. The company's results are reported figures; its planned Northstar Clear launch is an announced plan, not yet a shipped product.
Why it matters
The results show a diagnostics company growing revenue while keeping accumulated losses small relative to public peers, a pattern that matters as oncology testing becomes a larger share of its business. Management says it expects to sustain the current margin profile as oncology grows, which makes the coming quarters a test of whether growth and margins can hold together.
BillionToOne's reported third-quarter figures include a 71% gross margin and a $169 cost per test, which the company attributes partly to software automation and high test throughput. The accumulated-deficit comparison is a company-reported ratio against public peers, and the source does not specify the peer set or the time period used.
The players
BillionToOne
A diagnostics company whose oncology testing business includes the Northstar Response and planned Northstar Clear tests, and which reports GAAP profitability and positive cash flow.
The details
BillionToOne is a diagnostics company whose Northstar Response test monitors how a patient responds to treatment, and the company says it matched or beat a leading tissue-dependent test in a published head-to-head study. Northstar Clear, planned for launch on December 15, 2026, requires only a blood draw and avoids physical tumor tissue samples. Removing the need for physical tissue also eliminates processing delays for Northstar Response, according to the company. Higher average selling prices and growing oncology volume contributed to the revenue increase.
Timeline
November 4, 2026: BillionToOne held its third-quarter 2026 earnings call.
December 15, 2026: Planned commercial launch date for Northstar Clear.
The Tech Race
Northstar Clear is positioned as a blood-draw successor to tissue-based monitoring, which the company says removes sample-processing delays. The source does not name a specific competing effort against which this positioning is measured, so the competitive comparison rests on the company's own head-to-head study.
Patients whose oncologists use BillionToOne's tests may see treatment-response monitoring that does not require a physical tumor tissue sample, according to the company's plan for Northstar Clear. The source does not give pricing, insurance coverage, or availability beyond the planned December 15, 2026 launch date.
The takeaway
The trajectory to watch is whether BillionToOne keeps its 71% gross margin as oncology grows into a larger share of revenue. Track the planned December 15, 2026 commercial launch of Northstar Clear as the first test of whether the blood-draw approach reaches patients on schedule.
What happens next
BillionToOne plans to launch Northstar Clear on December 15, 2026, a date the company has set for commercial availability.
Further reading
Explore the latest Biotech developments shaping cancer diagnostics and treatment monitoring.





